#AAPG

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

2 weeks ago

Nouveaux appels à projets, #AAPG - résultats de l’étape 1, appel Flash Coopérations scientifiques France-Groenland, 18e édition du WISG, Trans Numériques #France2030 : découvrez la newsletter de février anr.fr/fileadmin/im...

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

2 weeks ago

📢 L’ANR publie les résultats de la première étape de l’Appel à projets générique 2026 ( #AAPG 2026).
Découvrez leur répartition par instrument de financement, par axe scientifique et par grand domaine disciplinaire
👉 anr.fr/fr/actus/det...

Thiard News@F4F

@newsen.bsky.social

1 month ago

Venezuela's Energy Potential Captures Global Attention Again, AAPG Provides Insight Amidst renewed global scrutiny, Venezuela's energy potential shines through as AAPG fosters crucial dialogues to inform industry stakeholders about geoscientific insights.

Venezuela's Energy Potential Captures Global Attention Again, AAPG Provides Insight #USA #Tulsa #Venezuela #AAPG #Geosciences

Thiard News@F4F

@newsen.bsky.social

1 month ago

Renewed Global Focus on Venezuela’s Energy Potential: Insights from AAPG Venezuela's energy landscape has captured global interest again. AAPG provides extensive geoscience insights on the challenges and opportunities in oil production.

Renewed Global Focus on Venezuela’s Energy Potential: Insights from AAPG #USA #Tulsa #AAPG #Venezuela_Oil #Energy_Potential

Thiard News@F4F

@newsen.bsky.social

1 month ago

Venezuela's Energy Revival: AAPG Offers Critical Insights and Analysis As Venezuela captures global interest, AAPG presents vital geoscience insights and technical discussions to guide industry players amidst complexities.

Venezuela's Energy Revival: AAPG Offers Critical Insights and Analysis #USA #Tulsa #Energy_Insights #AAPG #Venezuela_Oil

Thiard News@F4F

@newsen.bsky.social

1 month ago

Electricity Consumption Projects Massive Increase by 2035: AAPG Hosts Innovative Solutions Workshop Global electricity consumption is predicted to soar by 40% by 2035. AAPG gathers industry leaders to explore solutions for future energy needs.

Electricity Consumption Projects Massive Increase by 2035: AAPG Hosts Innovative Solutions Workshop #United_States #Houston #Energy_Solutions #Electricity_Demand #AAPG

StockTitan

@stocktitan.net

2 months ago

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference Ascentage Pharma (NASDAQ: AAPG) outlined its 2026 global innovation strategy at the 44th J.P. Morgan Healthcare Conference on Jan 15, 2026, highlighting a dual‑engine growth model led by commercial hematology drugs Olverembatinib and Lisaftoclax. The company received U.S. FDA IND clearance for APG-3288, a next‑generation BTK PROTAC degrader, and said multiple global registrational Phase III studies (GLORA, GLORA-4, POLARIS-1, POLARIS-2) are advancing. Other pipeline notes: APG-2449 entered global Phase III in NSCLC; APG-5918, APG-115, and APG-1252 progress in various indications. Commercial goals for 2026 include broader sales, coverage across 1,500 hospitals, and NRDL inclusion for Lisaftoclax in China.

#AAPG Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/AAPG/ascentage-phar...

StockTitan

@stocktitan.net

2 months ago

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 Ascentage Pharma (NASDAQ:AAPG) announced that the U.S. FDA has granted IND clearance for APG-3288, a next-generation BTK-targeted protein degrader, enabling a global, multicenter, open-label Phase I study in patients with relapsed/refractory B-cell malignancies.APG-3288 is a PROTAC-designed degrader intended to remove wild-type and multiple mutant BTK proteins, with preclinical data claiming higher potency, selectivity, and favorable PK versus other BTK degraders; clinical evaluation will assess safety, tolerability, PK, and preliminary efficacy.

#AAPG Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

www.stocktitan.net/news/AAPG/ascentage-phar...

StockTitan

@stocktitan.net

3 months ago

ASH 2025 76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles Strong efficacy data support potential advancement to earlier

#AAPG ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

www.stocktitan.net/news/AAPG/ash-2025-updat...

StockTitan

@stocktitan.net

3 months ago

ASH 2025 Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients 80% ORR achieved in newly diagnosed high-risk MDS/CMML Strong safety profile with no dose-limiting toxicities across all patient

#AAPG ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

www.stocktitan.net/news/AAPG/ash-2025-ascen...

StockTitan

@stocktitan.net

3 months ago

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment option Lisaftoclax achieved a 62.5% objective response rate (ORR) in

#AAPG Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

www.stocktitan.net/news/AAPG/ascentage-phar...

StockTitan

@stocktitan.net

3 months ago

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA Ascentage Pharma (NASDAQ: AAPG) announced that the US FDA and the EMA cleared a global registrational Phase III study (POLARIS-1; NCT06051409) of olverembatinib plus chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).The POLARIS-1 trial is a randomized, open-label, global study already initiated in China after CDE clearance in 2023 and is simultaneously enrolling across multiple countries to accelerate registration in the US and Europe. An ASH 2025 abstract reported ~65% MRD-negativity and molecular MRD-negative CR rates after three cycles and described a favorable safety profile. Olverembatinib is China-approved for drug-resistant CML, covered by the China NRDL, and is subject to an exclusive option agreement with Takeda (June 14, 2024). The drug is not yet FDA-approved in the US.

#AAPG Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

www.stocktitan.net/news/AAPG/ascentage-phar...

Thiard News@F4F

@newsen.bsky.social

3 months ago

AAPG Initiates Student Campaign to Revitalize Geoscience Workforce as Enrollment Plummets A newly launched campaign by AAPG aims to address a significant decline in geoscience enrollments and reinforce the next generation of energy workforce, focusing on student engagement and support.

AAPG Initiates Student Campaign to Revitalize Geoscience Workforce as Enrollment Plummets #Energy_Workforce #AAPG #Geoscience

AGU (American Geophysical Union)

@agu.org

5 months ago

Salt has been an essential commodity since prehistoric times, but recent advances have improved interpretations of salt structures. Learn more in the two-book set, Salt in the Earth Sciences. 📚

🎥 Watch the full interview with the author: buff.ly/wc9ZNZo

#evaporites #AAPG #salt #Geology #AGUPubs

Earth Science Week

@earthsciweek.bsky.social

5 months ago

Get ready for the ⚡️ energetic ⚡️ return of the #EarthScienceWeek #webinar series, from October 13th to 16th!

Don’t miss out on THE FUTURE of energy! 🛸

Register now - link in bio!

www.earthsciweek.org/webinars/

#energy #earthscience #future #NEED #geothermalrising #aapg #usgs #geology #geoscience

Rockd

@rockd.org

6 months ago

This update and #AAPG Foundation support position us for many great features to come.

As always, please let us know what you think!

Rockd

@rockd.org

6 months ago

Fun historical fact: most of the @macrostrat.org stratigraphic data for North America is derived from the COSUNA stratigraphic chart series.

Putting this seminal compilation a tap away from any geologist anywhere is a fitting way for #AAPG to honor the 40th anniversary of its creation!

Rockd

@rockd.org

6 months ago

Excited to inaugurate this feed to announce the release of Rockd Version 4, our first "major version" update since 2022! This renewed phase of app development was supported by the #AAPG Foundation.

It's mostly internal fixes for now, but there are some fun new features for geological exploration...

StockTitan

@stocktitan.net

6 months ago

Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of Lisaftoclax in China, following approval on July 10, 2025 by China’s NMPA for the

#AAPG Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates

www.stocktitan.net/news/AAPG/ascentage-phar...

@canadianapg.bsky.social

7 months ago

So grateful to our incredible sponsors for their generous support. Thank you for empowering this year’s conference to reach even greater heights!

Alberta Association of Police Governance – Friend Sponsor – $1,000

Learn more about our sponsors:

capg.ca/capgs-36th-a...

#CAPGVictoria2025 #AAPG

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

7 months ago

📢 Appel à projets générique #AAPG 2025 : l’ANR publie de nouvelles listes de projets sélectionnés incluant les projets sélectionnés au titre des priorités nationales et les projets classés en liste complémentaire.
➡ anr.fr/fr/detail/ca...

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

7 months ago

📝 L’ANR publie son Plan d’action et l’Appel à projets générique #AAPG 2026. Une année placée sous le signe de la continuité et de nouveaux dispositifs en matière de #Simplification, #Europe et #PartenariatPublicPrivé
En savoir ➕ anr.fr/fr/actualite...

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

7 months ago

📢 Appel à projets générique #AAPG 2025 : l’ANR publie de nouvelles listes de projets sélectionnés dans le cadre de 6 comités d’évaluation.
➡ anr.fr/fr/actualite...

UofA Map/GIS Librarian

@wyman10.bsky.social

8 months ago

Shows the entire length of: Log Salt Well No. I. Drilled by Alberta Government Fort McMurray [1947]. SCALE ~ 1 FT.= 80 FT. (1:960). Available in Internet Archive at: https://archive.org/details/WCWdb_WM_J272

[portion] of Log Salt Well No. I. Drilled by Alberta Government Fort McMurray [1947]. SCALE ~ 1 FT.= 80 FT. Layers or Strata (In order from the top of the Log Salt Well No. I. Loose Dirt 15′ Quick Sand 3′ Alluvial Mud 21.5′ White Sand 13′ Sand and Boulders 5′ Expressed by a number followed by ′ (prime symbol) equals a foot using the Imperial System of measurement. Available in Internet Archive at: https://archive.org/details/WCWdb_WM_J272

THE WATERWAYS FORMATION IN THE SUBSURFACE AT McMURRAY, ALBERTA. By W. D. MacDONALD In French: Compagnie Francaise des Petroles, Calgary, Alberta Text on page 105 related to Figure 1 A study of the subsurface Waterways formation, completed by the writer at the University of Alberta, Edmonton, in April 1947, was made from diamond cores of the three following wells: Alberta Government Salt Well No. 1 Industrial Minerals Salt Well No. I Industrial Minerals Salt Well No. 3 The accompanying map, Figure 1, shows the position of these wells at McMurray, Alberta. Full core recovery of the "Waterways formation was obtained on the two No. I wells, while the Industrial Minerals No. 3 well was partially cored. Record found in: American Association of Petroleum Geologists (AAPG) Datapages, Inc. Archives https://archives.datapages.com/data/cspg/data/003/003007/pdfs/0105.pdf

THE WATERWAYS FORMATION IN THE SUBSURFACE AT McMURRAY, ALBERTA. By W. D. MacDONALD [portion] of Figure 1 showing location of "Alberta Gov't Salt Well No. 1" in the "McMurray Townsite" https://archives.datapages.com/data/cspg/data/003/003007/pdfs/0105.pdf

#Tilde in a #VerbalScale alert
SCALE ~ 1 FT.= 80 FT.
Who wants to ratio this ~ about?
Also - Quick Sand!

Log Salt Well No. I. Drilled by AB Government Fort McMurray [1947] archive.org/details/WCWd...

#VerbalScale tinyurl.com/a5k8vwn6
#Tilde en.wikipedia.org/wiki/Tilde
#AAPG #SaltWell #FortMcMurray

StockTitan

@stocktitan.net

8 months ago

Ascentage Pharma Announces Pricing of Top-Up Placement Ascentage Pharma (NASDAQ: AAPG) has announced the pricing of a significant share placement involving 22 million ordinary shares at HKD68.60 per share. The placement, conducted by CEO Dajun Yang's affiliated trust, will generate gross proceeds of approximately HKD1,509.2 million (US$192.3 million).The highly successful offshore placement was oversubscribed by eight times and is expected to close on July 17, 2025. Following the placement, the CEO's trust will subscribe to an equal number of new shares at the same price. The company plans to use the proceeds for commercialization efforts, global clinical development of core pipeline candidates, and strengthening global operations.

#AAPG Ascentage Pharma Announces Pricing of Top-Up Placement

www.stocktitan.net/news/AAPG/ascentage-phar...

StockTitan

@stocktitan.net

8 months ago

Ascentage Pharma Announces Proposed Top-Up Placement Ascentage Pharma (NASDAQ: AAPG) has announced a proposed top-up placement involving two key transactions. First, Dajun Yang Dynasty Trust, affiliated with the company's CEO, will offer ordinary shares in an offshore transaction to non-U.S. persons under Regulation S. Second, the Trust will subscribe to new company shares (Replacement Shares) at the same quantity and price as the offshore placement.The proceeds from this offering will fund commercialization efforts, global clinical development of core pipeline candidates, and strengthen global operations. The placement shares will not be registered under U.S. Securities Act and won't be offered to the public in Hong Kong.

#AAPG Ascentage Pharma Announces Proposed Top-Up Placement

www.stocktitan.net/news/AAPG/ascentage-phar...

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

8 months ago

📢 Appel à projets générique #AAPG 2025 : l’ANR publie de nouvelles listes de projets sélectionnés dans le cadre de 13 comités d’évaluation.
➡ anr.fr/fr/actualite...

StockTitan

@stocktitan.net

8 months ago

Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL Ascentage Pharma (NASDAQ: AAPG) has achieved a significant milestone with the China NMPA approval of lisaftoclax, its novel Bcl-2 inhibitor, for treating adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received prior systemic therapy including BTK inhibitors.The approval is based on a pivotal Phase II study where lisaftoclax demonstrated compelling efficacy and favorable safety profile, with no tumor-lysis syndrome and manageable toxicities. This makes lisaftoclax the first Bcl-2 inhibitor approved in China for CLL/SLL treatment and only the second globally.The drug addresses a significant unmet need in China, where CLL/SLL incidence is rising rapidly with younger onset age. Lisaftoclax was recently included in the 2025 Chinese Society of Clinical Oncology Guidelines, and Ascentage is currently conducting four global Phase III trials exploring additional indications.

#AAPG Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL

www.stocktitan.net/news/AAPG/ascentage-phar...

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

8 months ago

📢 Appel à projets générique #AAPG 2025 : l’ANR publie de nouvelles listes de projets sélectionnés dans le cadre de 17 comités d’évaluation.
➡ anr.fr/fr/actualite...

ANR - Agence nationale de la recherche

@agencerecherche.bsky.social

8 months ago

📢 Appel à projets générique #AAPG 2025 : l’ANR publie les premières listes de projets sélectionnés dans le cadre de 21 comités d’évaluation.
➡ anr.fr/fr/actualite...